Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Interventions
Renal Autologous Cell Therapy (REACT/ rilparencel), Sham Comparator
Biological · Procedure
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
685 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
79
States / cities
Huntsville, Alabama • Tucson, Arizona • Beverly Hills, California + 63 more
Conditions
Low Anterior Resection Syndrome, Malignant Anal Neoplasm, Malignant Bladder Neoplasm, Malignant Cervical Neoplasm, Malignant Ovarian Neoplasm, Malignant Pelvic Neoplasm, Malignant Prostate Neoplasm, Malignant Uterine Neoplasm, Malignant Vaginal Neoplasm, Malignant Vulvar Neoplasm, Rectal Carcinoma
Interventions
Explantation, Quality-of-Life Assessment, Questionnaire Administration, Sacral Nerve Stimulator, Sacral Nerve Stimulator Battery, Therapeutic Conventional Surgery
Procedure · Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Houston, Texas • Sugar Land, Texas
Completed Phase 2 Interventional Results available

Adj TC + Herceptin Early Stage Breast Cancer

NCT00493649
Conditions
Breast Cancer
Interventions
Taxotere, Cytoxan, Herceptin
Drug
Lead sponsor
US Oncology Research
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
69
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 62 more
Active, not recruiting No phase listed Observational

Breast Cancer Index (BCI) Registry

NCT04875351
Conditions
Breast Cancer
Interventions
Breast Cancer Index (BCI) Risk of Recurrence & Extended Endocrine Benefit Test
Diagnostic Test
Lead sponsor
Biotheranostics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
3,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
105
States / cities
Daphne, Alabama • Mobile, Alabama • Glendale, Arizona + 84 more
Conditions
AL Amyloidosis
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biopsy, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bortezomib, Computed Tomography, Cyclophosphamide, Daratumumab and Hyaluronidase-fihj, Dexamethasone, Echocardiography, Magnetic Resonance Imaging, Melphalan, Positron Emission Tomography, Stem Cell Isolation, Survey Administration
Procedure · Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
338 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
117
States / cities
Goodyear, Arizona • Tucson, Arizona • Duarte, California + 93 more
Conditions
Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Lip and Oral Cavity Squamous Cell Carcinoma, p16INK4a Negative Oropharyngeal Squamous Cell Carcinoma, Stage III Hypopharyngeal Carcinoma AJCC v8, Stage III Laryngeal Cancer AJCC v8, Stage III Lip and Oral Cavity Cancer AJCC v8, Stage III Oral Cavity Verrucous Carcinoma, Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8, Stage IVA Hypopharyngeal Carcinoma AJCC v8, Stage IVA Laryngeal Cancer AJCC v8, Stage IVA Lip and Oral Cavity Cancer AJCC v8, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Interventions
Cisplatin, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
Drug · Radiation · Other
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
676
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 446 more
Conditions
Bradycardia
Interventions
Cardiac pacing
Device
Lead sponsor
Duke University
Other
Eligibility
1 Day and older
Enrollment
1,383 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
8
States / cities
Sarasota, Florida • Chicago, Illinois • Indianapolis, Indiana + 5 more
Not listed Not applicable Interventional Accepts healthy volunteers

Safety and Feasibility of ActivSightTM in Human

NCT04633512
Conditions
Acute Cholecystitis, Colorectal Cancer, Diverticulitis, Colonic, Obesity, Morbid, Inflammatory Bowel Diseases
Interventions
ActivSight
Device
Lead sponsor
Activ Surgical
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
3
States / cities
Buffalo, New York • Houston, Texas • Sugar Land, Texas
Conditions
Atypical Endometrial Hyperplasia, Stage I Uterine Corpus Cancer AJCC v7, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7
Interventions
Laboratory Biomarker Analysis, Levonorgestrel-Releasing Intrauterine System, Quality-of-Life Assessment
Other · Device
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2027
U.S. locations
7
States / cities
Houston, Texas • Nassau Bay, Texas • Sugar Land, Texas + 1 more
Conditions
Uterine Fibroid, Endometriosis
Interventions
Not listed
Lead sponsor
Myovant Sciences GmbH
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
660 participants
Timeline
2018 – 2020
U.S. locations
37
States / cities
Mobile, Alabama • Mesa, Arizona • Huntington Beach, California + 31 more
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
262
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
Conditions
Inflammatory Breast Carcinoma, Invasive Breast Carcinoma, Second Primary Malignant Neoplasm
Interventions
Biospecimen Collection, Interview, Medical Chart Review, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2030
U.S. locations
10
States / cities
Gilbert, Arizona • La Jolla, California • Greeley, Colorado + 6 more
Conditions
Non-small Cell Carcinoma, Non-Small Cell Lung Cancer Metastatic, Non-Small Cell Lung Carcinoma
Interventions
PF-08046054, Docetaxel monotherapy
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
197
States / cities
Alabaster, Alabama • Bessemer, Alabama • Birmingham, Alabama + 135 more
Conditions
Influenza, Human
Interventions
aQIV or aTIV, QIV or TIV
Biological
Lead sponsor
Seqirus
Industry
Eligibility
65 Years and older
Enrollment
38,769 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
111
States / cities
Birmingham, Alabama • Cullman, Alabama • Phoenix, Arizona + 95 more
Conditions
Colon Adenocarcinoma, Stage IIA Colon Cancer AJCC v8
Interventions
Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Patient Observation
Drug · Other
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
635 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
932
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 639 more
Conditions
Cognitive/Functional Effects, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
intensity-modulated radiation therapy
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
60
States / cities
Birmingham, Alabama • Peoria, Arizona • Scottsdale, Arizona + 51 more
Conditions
Oligometastatic Malignant Solid Neoplasm
Interventions
Best Practice, Local Consolidation Therapy
Other · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
12
States / cities
Gilbert, Arizona • Little Rock, Arkansas • Honolulu, Hawaii + 8 more
Conditions
Stage III Colon Cancer
Interventions
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
Device · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
1023
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 710 more
Conditions
Asthma
Interventions
Omalizumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
12 Years and older
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
145
States / cities
Birmingham, Alabama • Huntsville, Alabama • Gilbert, Arizona + 125 more
Conditions
Cataract
Interventions
ARGOS biometer, IOLMaster 700
Diagnostic Test
Lead sponsor
Berkeley Eye Center
Other
Eligibility
45 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Sugar Land, Texas
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Early Stage HER2+ Breast Cancer
Interventions
Trastuzumab (Herceptin), Pertuzumab, Echocardiography, Multigated Acquisition Scan, Mammography, Ultrasound, Magnetic Resonance Imaging, Biospecimen Collection, Questionnaire Administration
Biological · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,524 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
667
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Jonesboro, Arkansas + 514 more
Conditions
Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Binimetinib, Biopsy Procedure, Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Palbociclib
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
265
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 207 more
Conditions
Breast Cancer, Triple Negative Breast Cancer
Interventions
Everolimus
Drug
Lead sponsor
Jenny C. Chang, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
Houston, Texas • Sugar Land, Texas
Conditions
Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage IB2 Cervical Cancer AJCC v6 and v7, Stage II Cervical Cancer AJCC v7, Stage II Vaginal Cancer AJCC v6 and v7, Stage IIA Cervical Cancer AJCC v7, Stage IIB Cervical Cancer AJCC v6 and v7, Stage III Vaginal Cancer AJCC v6 and v7, Stage IIIB Cervical Cancer AJCC v6 and v7, Stage IV Vaginal Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVA Vaginal Cancer AJCC v6 and v7, Unresectable Vaginal Carcinoma, Vaginal Adenocarcinoma, Vaginal Adenosquamous Carcinoma, Vaginal Carcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
Interventions
Brachytherapy, Cisplatin, External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis, Radiation Therapy, Triapine
Radiation · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
377
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 253 more